



BD Neopak™

Glass Pre-fillable Syringe

Give tomorrow's most demanding biotech drugs the strength of BD Neopak™ Pre-fillable Syringe technology



Biotech drugs that are breakthroughs or that target new therapeutic areas

The overriding challenge facing Biopharmaceutical companies today is the **increasing pressure** around **time to market**. Critical success factors influencing pipeline drug therapies development and market launch on time are:

- Risk mitigation associated with **drug-container interactions**
- Anticipation of **combination product development**
- Anticipation of market **demand expansion**






BD Neopak™ Glass Pre-fillable Syringe is built on years of BD's unmatched experience partnering with leading biopharmaceutical companies to support drug development and launch. BD Neopak™ was conceived with a solution-seeking mindset, allowing to tangibly meet your current and future needs for biotech drugs.

- > BD Neopak™ Glass Pre-fillable Syringe platform covers a broad design space for agile development, supporting your time-to-market



BD Neopak™ Glass Pre-fillable Syringe platform covers a broad design space for agile development to support your time-to-market

- BD Neopak™ offers a wide portfolio of options

Barrel format	Needles gauge	Needle shield	Flange design
1 mL & 2.25 mL 	<div style="display: flex; justify-content: space-around;"> <div style="text-align: center;"> <p>BD PhysioliS™</p>  <p>29G TW</p> </div> <div style="text-align: center;"> <p>BD Hyflow™</p>  <p>27G RW 27G STW</p> </div> </div>	Rigid needle shield rubber formulations: BD260, FM30, 4800	Cut Flange Small Round Flange Small Extra-round Flange
<p>+ BD Neopak™ gives you access to BD advanced technologies Facilitating implementation of new solutions</p> <ul style="list-style-type: none"> ▶ BD Neopak™ XSi™ Glass Pre-fillable Syringe with silicone immobilization technology  ▶ BD VisioGuard™ Stopper Stopper visual-inspection technology  			

- BD Neopak™ is designed to ensure compatibility with BD injection systems *

BD UltraSafe Plus™ Passive Needle Guard	BD Intevia™ Disposable Autoinjector (1 mL-2.25 mL)	BD Libertas™ Wearable Injector
		

*BD Intevia™, BD Libertas™, UltraSafe Plus™ 2.25, are products in development and are subject to a variety of risks and uncertainties

BD integrated system approach facilitates further development to support launch and shorter time-to-market



- BD Neopak™ extensive track record and associated BD services to support your combination product development:
 - > BD Neopak™ is uniquely supported by a **wealth of data** on extractable, biocompatibility, stability and device compatibility
 - > BD Regulatory Affairs offer* a full “container closure system” **regulatory data package** ensuring information accuracy and simplifying your CTD** registration process
 - * On a customer case by case basis ** CTD = Common Technical Document
 - > BD Technical Services offer **drug-container compatibility testing**, using validated methods and BD state-of-the-art equipments

BD Medical
Pharmaceutical Systems
United States
1 Becton Drive
Franklin Lakes, NJ 07417
+1 800 225 3310
Europe
11 rue Aristide-Bergès
38800 Le Pont-de-Claix
France
Phone: +33 4 76 68 36 36
Fax: +33 4 76 68 35 05
Becton Dickinson France S.A.S
Share capital: 64 719 915 €
RCS Grenoble B 056 501 711

bd.com

BD, the BD Logo, BD Hypak, BD Intevia, BD Libertas, BD Neopak, BD Neopak XSi, BD PhysioliS, BD UltraSafe Plus, and BD VisioGuard are property of Becton, Dickinson and Company, or its affiliates. © 2020 BD. All rights reserved.

